首页>
外国专利>
THERAPEUTIC TARGETING OF PARC/CCL18 AND ITS SIGNALING IN PULMONARY FIBROSIS
THERAPEUTIC TARGETING OF PARC/CCL18 AND ITS SIGNALING IN PULMONARY FIBROSIS
展开▼
机译:PARC / CCL18的靶向治疗及其在肺纤维化中的作用
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to methods of treating, preventing or preventing the progression of fibrosis comprising inhibiting the actions of pulmonary and activation-regulated chemokine (PARC) or at least one of its downstream effector molecules, such as Sp1 transcription factor and protein kinase C-alpha (PKCα). The present invention also relates to methods of screening and/or identifying compounds useful for the treatment of fibrosis comprising contacting PARC or its downstream effector molecules, such as Sp1 or PKCα, with a substance and subsequently determining the effects of the substance on the activity of PARC or Sp1 or PKCα. The present invention also relates to methods of screening and/or identifying compounds that prevent or inhibit collagen deposition comprising contacting PARC or its downstream effector molecules, such as Sp1 or PKCα, with a substance and subsequently determining the effects of the substance on the activity of PARC or Sp1 or PKCα.
展开▼